Articles tagged "Liver transplantation"

2019 American Transplant Congress
Validation Of The Optimized Prediction Of Mortality (Opom) Machine Learning Model For Non-hepatocellular Carcinoma Candidates Awaiting Liver Transplant
L. Lau¹, X. Xie², F. Jia², P. D. Greig¹, T. C. Chan²
¹Multi-Organ Transplant, Department of Surgery, University of Toronto, Toronto, ON, Canada, ²Mechanical and Industrial Engineering, University of Toronto, Toronto, ON, Canada
*Purpose: Currently the Model for End-Stage Liver Disease (MELD) is used to rank candidates for liver transplant in many jurisdictions. However, MELD does not provide…
2019 American Transplant Congress
An Open-Label Proof-of-Principle Phase 2A Study to Evaluate Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance (ASCOTT)
A. Chruscinski¹, H. Atkins², A. Clement², D. Grant¹, C. Bredsen², E. Renner¹, J. Zhang¹, M. Epstein¹, L. Lilly¹, N. Selzner¹, O. Adeyi¹, R. Smith¹, S. Moshkelgosha¹, A. Humar¹, S. Juvet¹, G. Levy¹
¹Multi-Organ Transplantation, University Health Network, Toronto, ON, Canada, ²Ottawa Hospital Research Institute, Ottawa, ON, Canada
*Purpose: Long-term survival of recipients of solid organ transplants is hampered by chronic rejection, disease recurrence and immunosuppression-induced toxicity. Self-tolerance is re-established after autologous hematopoietic…
2019 American Transplant Congress
The Impact of Portal Flow after Reperfusion on Graft Outcomes after Deceased Donor Liver Transplantation
H. Matsushima, K. Sasaki, M. Fujiki, T. Diago Uso, B. Eghtesad, F. Aucejo, C. Kwon, C. Miller, C. Quintini, K. Hashimoto
General Surgery, Digestive Disease & Surgery Institute, Cleveland Clinic, Cleveland Clinic, Cleveland, OH
*Purpose: The impacts of intraoperative portal flow (PF) on graft outcomes after living donor liver transplantation have been studied well, however, its impact on graft…
2019 American Transplant Congress
Presence of DSA Class 2 is Associated with Fibrosis Progression after OLT
M. Sterneck¹, B. Sultani², M. Rodriguez Lago³, E. Grabhorn⁴, A. Briem-Richter⁴, U. Herden⁵, L. Fischer⁵
¹University Medical Center Hamburg Eppendorf, Hamburg, Germany, ²University Transplant Center, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ³Depatment of Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁴Department of Paediatric Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁵Department of Visceral Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
*Purpose: For decades, donor-specific antibodies (DSA) have been thought not to be clinically relevant in orthotopic liver transplantation (OLT). However, recent studies have shown a…
2019 American Transplant Congress
Patterns and Predictors of Alcohol Use after Early Liver Transplant for Alcoholic Hepatitis
B. P. Lee¹, M. Rinella², G. Im³, J. Rice⁴, O. Fix⁵, G. Therapondos⁶, H. Han⁷, D. Victor⁸, E. Weinberg⁹, C. Hsu¹⁰, M. Voigt¹¹, H. Maddur², S. Eswaran¹², D. Foley⁴, R. Ghobrial⁸, L. Dinges⁵, J. Dodge¹, N. Mehta¹, M. Lucey⁴, N. Terrault¹
¹UCSF, SF, CA, ²NW, Chicago, IL, ³MtSinai, NYC, NY, ⁴Wisconsin, Madison, WI, ⁵Swedish, Seattle, WA, ⁶Ochsner, Jefferson, LA, ⁷USC, LA, CA, ⁸Houston, Houston, TX, ⁹Penn, Philadelphia, PA, ¹⁰Georgetown, DC, WA, ¹¹Iowa, Iowa City, IA, ¹²Rush, Chicago, IL
*Purpose: ACCELERATE-AH is a multicenter consortium studying early liver transplant (LT) for alcoholic hepatitis (AH). To inform surveillance and intervention strategies for post-LT alcohol use,…
2019 American Transplant Congress
Hepatoblastoma Tumors Requiring Liver Transplantation Manifest Dysregulated Ciliary, Autophagy and Cell Cycling Pathways in Systems Biology Analysis
T. Narayanan¹, M. Ningappa², B. W. Higgs², S. Subramaniam³, R. Sindhi²
¹Bioenginering, University of California, San Diego, CA, ²Childrens Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ³University of California, San Diego, CA
*Purpose: Liver transplantation (LT) can cure locally invasive, unresectable and chemo-resistant hepatoblastoma (HBL), an embryonal liver tumor of infancy. Post-LT immunosuppression enhances recurrence-risk despite chemotherapy.*Methods:…
2019 American Transplant Congress
The Effect of Lifestyle Intervention on Physical Functionality, Progress of Liver Disease and Mortality in Decompensated Cirrhosis Patients in a Community Model
S. Habib, F. Alsafar
Liver Institute PLLC, Tucson, AZ
*Purpose: The study was designed to look at relationships between diet and exercise interventions and liver disease prognosis in terms of survival and ability to…
2019 American Transplant Congress
Targeted Antifungal Prophylaxis in Liver Transplant Recipients: Two Year, Retrospective Cohort Analysis
N. Persun¹, J. Doyon², E. Blumberg², S. Prenner², V. Khungar², P. Abt³, C. Sammons¹
¹Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ³Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA
*Purpose: No consensus exists regarding systemic antifungal prophylaxis in liver transplant recipients (LTRs) in terms of optimal duration, choice of agent, or risk factors to…
2019 American Transplant Congress
Evaluation of Liver Function and Biomarkers Predicts Tumor Progression in Treatment-Naïve Hepatocellular Carinoma Patients
K. Nunez, T. Sandow, S. Robertson, P. Thevenot, A. Cohen
Ochsner Health System, New Orleans, LA
*Purpose: Hepatocellular carcinoma (HCC) is the 3rd leading cause of cancer-related deaths in the world with recurrence rates at 40%. Locoregional therapy (LRT) is standard…
2019 American Transplant Congress
Impact of Hepatitis C Viremia on Post-Transplant Diabetes Mellitus Development in Liver Transplant Recipients
K. Klein¹, J. Nelson², B. Crowther¹, C. Guerra³, E. Kincaide¹, K. V. Speeg⁴, N. Alkhouri⁵, R. Hall¹
¹University Health System, The University of Texas at Austin, College of Pharmacy, Pharmacotherapy Division, Austin, TX, The University of Texas Health Science Center at San Antonio, San Antonio, TX, ²University Health System, San Antonio, TX, ³The University of Texas Health Science Center at San Antonio, University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX, ⁴University Health System, The University of Texas Health Science Center at San Antonio, San Antonio, TX, ⁵University Health System, The University of Texas Health Science Center at San Antonio, Texas Liver Institute, San Antonio, TX
*Purpose: Compare incidence of post-transplant diabetes mellitus (PTDM) in hepatitis C virus (HCV) patients with and without viremia at the time of orthotopic liver transplantation…